NJFU: the Difference of Follow-up Methods of Neonatal Jaundice

Sponsor
Guizhou Provincial People's Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06075290
Collaborator
(none)
1,000
3
19
333.3
17.6

Study Details

Study Description

Brief Summary

The goal of this observational study is to compare the effectiveness and efficiency for precaution of severe hyperbilirubinemia in neonate by different follow-up methods of neonatal jaundice. There are two kinds of follow-up methods in our clinical practice. The one is internet plus follow-up model, the other is conventional clinic follow-up method. Parents of the participant neonates can choose one by themselves. After they signed informed consent, we recorded several information including severe hyperbilirubinemia, length of phototherapy, follow-up times, et al. Then we analysed these data in order to know what kind of follow-up method is better to prevent severe hyperbilirubinemia and more easy to accept.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: internet plus model
  • Behavioral: control

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Application of Two Different Follow-up Methods for Neonatal Jaundice in the Prevention of Severe Hyperbilirubinemia
Anticipated Study Start Date :
Oct 10, 2023
Anticipated Primary Completion Date :
Oct 10, 2024
Anticipated Study Completion Date :
May 10, 2025

Arms and Interventions

Arm Intervention/Treatment
Observation group

Intelligent jaundice instrument and Internet plus system for home monitoring and remote follow-up

Behavioral: internet plus model
Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up

control group

follow-up by conventional methods ; hospital or community follow-up depending on arrangement

Behavioral: control
follow-up by conventional methods; hospital or community follow-up depending on arrangement

Outcome Measures

Primary Outcome Measures

  1. Incidence of severe hyperbilirubinemia [10,01,2023 to 10,01,2024]

    The peak concentration of serum bilirubin is more than the exchange criteria of same gestational age and day age group

  2. Newborn follow-up rate [10,01,2023 to 10,01,2024]

    Number of newborns who completed the follow-up program/total number of follow-up newborns

Secondary Outcome Measures

  1. Incidence rate of acute bilirubin encephalopathy [10,01,2023 to 10,01,2024]

    Number of infants with acute bilirubin encephalopathy/total number of follow-up newborns

  2. Mean bilirubin level at admission [10,01,2023 to 10,01,2024]

    sum total serum bilirubin of hospitalized newborns at admission/Total number of hospitalized newborns

  3. Follow-up satisfaction [10,01,2023 to 10,01,2024]

    Parents' comments of participating in the study

  4. Average economic cost of treatment [10,01,2023 to 10,01,2024]

    Treatment and transportation costs and so on

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Days to 16 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Gestational age ≥ 28 weeks, corrected gestational age ≤ 44 weeks;

  2. Presence of skin yellowing, percutaneous measurement of jaundice or serum bilirubin concentration less than the phototherapy warning value for the same gestational age and day age group;

  3. The vital signs are stable and meet the discharge requirements;

  4. Agree to participate in this project and sign an informed consent form;

  5. Parents have a certain understanding ability to cooperate in this study;

Exclusion Criteria:
  1. Direct bilirubin ≥34mmol/L;

  2. Increased hepatic enzyme level more than twice of normal value;

  3. Those infants who have developed bilirubin encephalopathy or neurological damage due to other reasons before follow-up;

  4. Unable to continue follow-up due to other diseases.

Contacts and Locations

Locations

Site City State Country Postal Code
1 People's Hospital of Anshun City Guizhou Province Anshun Guizhou China 561001
2 The First Affiliated Hospital of Guizhou University of Chinese Guiyang Guizhou China 550001
3 Guizhou Provincial People's Hospital Guiyang Guizhou China 550002

Sponsors and Collaborators

  • Guizhou Provincial People's Hospital

Investigators

  • Principal Investigator: Rong Chen, doctor, Guizhou Provincial People's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Guizhou Provincial People's Hospital
ClinicalTrials.gov Identifier:
NCT06075290
Other Study ID Numbers:
  • NEO20230802
First Posted:
Oct 10, 2023
Last Update Posted:
Oct 10, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Guizhou Provincial People's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2023